Leukemia Clinical Trials in Detroit

Showing 1061-1080 of 1,440 trials

Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage

NCT00009620

This large randomized trial tested whether phenobarbital given to a pregnant woman about to deliver a premature infant would prevent brain injuries in their newborns. Women with 24 to 32 week fetuses who were in preterm labor and were expected to deliver within 24 hrs were randomized to phenobarbital or usual care. They were treated until they deliver or the fetus reaches 33 wks gestation. Babies were followed until discharge and evaluated at 18-22 mos corrected age for neurodevelopmental outcome.

Infant, NewbornInfant, Low Birth WeightInfant, Small for Gestational Age+2 more

NICHD Neonatal Research Network610 participantsStarted Feb 1993

Palo Alto, California, United States • New Haven, Connecticut, United States • Washington D.C., District of Columbia, United States +8 more locations

COMPLETEDPhase 2/3< 1 mile

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

NCT01203358

The purpose of this study is to compare the efficacy of two surfactants, Exosurf Neonatal (Burroughs Wellcome Co.) and Survanta (Ross Laboratories), for the treatment of neonatal respiratory distress syndrome.

Infant, NewbornInfant, Low Birth WeightInfant, Small for Gestational Age+2 more

NICHD Neonatal Research Network617 participantsStarted Jan 1991

Palo Alto, California, United States • New Haven, Connecticut, United States • Washington D.C., District of Columbia, United States +10 more locations

Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

Leukemia Trials in Other Cities

Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study

Observational Study of Surgical Treatment of Necrotizing Enterocolotis

Early Diagnosis of Candidiasis in Premature Infants

Immunogenicity of PCV-7 Vaccine in VLBW Infants

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia

Other Conditions in Detroit